First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

This is a first-in-human study of ATX-295, a new oral (taken by mouth) drug that blocks a protein called KIF18A — a protein that cancer cells rely on to divide. It is being tested in patients with advanced or metastatic solid tumors, with a particular focus on ovarian cancer, including platinum-resistant high-grade serous ovarian cancer (HGSOC). **You may be eligible if...** - You have been diagnosed with a solid tumor (such as ovarian cancer) that is advanced or has spread - You have tried all standard available treatments, or your doctor believes standard treatment is not appropriate for you - For the ovarian cancer expansion cohort: you must have high-grade serous ovarian cancer that is platinum-resistant, platinum-refractory, or platinum-intolerant - You have measurable or evaluable disease on imaging - You are in adequate health (ECOG performance status meeting criteria) **You may NOT be eligible if...** - You have never tried standard treatments and are a suitable candidate for them - Your organ function does not meet the required thresholds - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.